In this review, we will summarize the recent advances in hypofractionated and accelerated partial breast irradiation and discuss the ongoing clinical trials that utilize existing validated genomic classifiers and immunohistochemistry-based assays for risk categorization and radiation omission in hormone receptor-positive early breast cancers. Here, NR4A1 is linked to breast carcinoma.